While Lexicon Pharmaceuticals Inc has overperformed by 0.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LXRX rose by 99.05%, with highs and lows ranging from $1.66 to $0.28, whereas the simple moving average jumped by 59.93% in the last 200 days.
On March 05, 2025, Leerink Partners Downgraded Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) to Market Perform. A report published by H.C. Wainwright on June 17, 2024, Initiated its previous ‘Buy’ rating for LXRX. Leerink Partners also rated LXRX shares as ‘Outperform’, setting a target price of $5 on the company’s shares in an initiating report dated April 30, 2024. Jefferies Initiated an Hold rating on March 07, 2023, and assigned a price target of $3. Piper Sandler initiated its ‘Overweight’ rating for LXRX, as published in its report on August 12, 2022. JP Morgan’s report from January 29, 2021 suggests a price prediction of $7 for LXRX shares, giving the stock a ‘Neutral’ rating. Wedbush also rated the stock as ‘Neutral’.
Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Further, the quarter-over-quarter increase in sales is 710.40%, showing a positive trend in the upcoming months.
One of the most important indicators of Lexicon Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -45.92% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.63, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and LXRX is recording 2.33M average volume. On a monthly basis, the volatility of the stock is set at 7.51%, whereas on a weekly basis, it is put at 7.25%, with a loss of -5.77% over the past seven days. Furthermore, long-term investors anticipate a median target price of $2.88, showing growth from the present price of $1.47, which can serve as yet another indication of whether LXRX is worth investing in or should be passed over.
How Do You Analyze Lexicon Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 49.37%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 23.63% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
